



Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

May 31, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 31, 2023-- [Kezar Life Sciences, Inc.](#) (Nasdaq: [KZR](#)), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-Founder and Chief Executive Officer, and Noreen R. Henig, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 2:00 pm ET in New York, NY.

A webcast of the fireside chat will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230531005125/en/): <https://www.businesswire.com/news/home/20230531005125/en/>

Investor Contact:

Gitanjali Jain
Vice President, Investor Relations and External Affairs
gjain@kezarbio.com

Media Contact:

Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com

Source: Kezar Life Sciences, Inc.